KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $57.4 million.

  • Emergent BioSolutions' Accounts Payables fell 3008.53% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.4 million, marking a year-over-year decrease of 3008.53%. This contributed to the annual value of $60.9 million for FY2024, which is 4572.19% down from last year.
  • Emergent BioSolutions' Accounts Payables amounted to $57.4 million in Q3 2025, which was down 3008.53% from $63.7 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Accounts Payables high stood at $151.8 million for Q2 2021, and its period low was $57.4 million during Q3 2025.
  • In the last 5 years, Emergent BioSolutions' Accounts Payables had a median value of $106.2 million in 2022 and averaged $102.7 million.
  • Per our database at Business Quant, Emergent BioSolutions' Accounts Payables skyrocketed by 7900.94% in 2021 and then tumbled by 4572.19% in 2024.
  • Emergent BioSolutions' Accounts Payables (Quarter) stood at $128.9 million in 2021, then decreased by 19.71% to $103.5 million in 2022, then grew by 8.41% to $112.2 million in 2023, then tumbled by 45.72% to $60.9 million in 2024, then decreased by 5.75% to $57.4 million in 2025.
  • Its last three reported values are $57.4 million in Q3 2025, $63.7 million for Q2 2025, and $58.1 million during Q1 2025.